Home / Health / Nimesulide Ban: India Re-evaluates Painkiller Risks
Nimesulide Ban: India Re-evaluates Painkiller Risks
10 Jan
Summary
- Nimesulide offered quick pain relief but posed significant liver risks.
- Studies link high doses and prolonged use to severe liver damage.
- Several European countries banned Nimesulide years ago due to side effects.
Nimesulide, a painkiller popular in India for its rapid effectiveness, is facing renewed attention due to its safety profile. While widely used for fever and pain, emerging evidence over decades highlights risks associated with high dosages and extended treatment periods. Concerns about hepatotoxicity, including liver damage and failure, have led to regulatory actions.
Studies have indicated a significant risk of acute liver injury within 30 days of use, with some cases requiring transplantation or proving fatal. These findings prompted bans in European nations like Finland and Spain as early as 2002, followed by Ireland, Malaysia, Singapore, Vietnam, and Argentina in subsequent years.
Health professionals now advise patients on Nimesulide to consult healthcare providers for immediate discontinuation. Alternative pain management strategies, including physiotherapy, lifestyle adjustments, and other NSAIDs like ibuprofen or diclofenac at approved doses, are being promoted as safer options.
